Influenza Vaccination in the Emergency Department

NCT00822627 | Completed

• 1 other identifier: 1
• Study Type: interventional
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

Randomized controlled trial of influenza vaccination versus referral for vaccination in the Emergency department. Is the Emergency Department an effective venue for vaccination for influenza? Does vaccination for influenza in the Emergency Department change the rates of influenza, influenza-like-illness or medical provider visits when compared with patient referred for vaccination in the community?

Conditions

Influenza

Keywords

Influenza; vaccination; Emergency Department

Outcome Measures

Primary Outcomes (1)

• Vaccination status

  4 months

Secondary Outcomes (3)

• Influenza rate

  4 months

• Influenza-like illness rate

  4 months

• Visits to medical providers

  4 months

Study Arms (2)

Vaccination group

EXPERIMENTAL

Vaccination group

Drug: Influenza Vaccination

Education/referral

EXPERIMENTAL

Education/referral

Behavioral: Education and referral

Interventions

Influenza Vaccination DRUG

0.5 mL Sanofi-Pasteur intramuscular influenza vaccination

Vaccination group

Education and referral BEHAVIORAL

Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination

Education/referral

Eligibility Criteria

• Age: 6 Months+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Unvaccinated patients presenting to the Emergency Department aged 6 months or more who have at least one high risk attribute:
• Age 6-59 months or \>50 years
• Pregnant
• Health care worker
• Aged 6 months-18 years on chronic aspirin therapy
• Comorbidity (cardiovascular disease, pulmonary disease, metabolic disease, renal disease, hepatic disease, seizures, neuromuscular disease, cognitive dysfunction, or any reason to have had regular medical follow up or hospitalization in the preceding year)
• Household contact or caregiver of someone with at least one high risk attribute

You may not qualify if:

• Prior vaccination
• History of Guillan-Barre syndrome within 6 weeks of prior influenza vaccination
• Allergy to influenza vaccination or eggs
• Age \< 6 months old
• Fever with more than minor illness
• Hospitalization

Sponsors & Collaborators

• University of Arizona: lead

Study Sites (1)

University of Arizona

Tucson, Arizona, 85724, United States

Location

MeSH Terms

Conditions

Influenza, Human; Emergencies

Interventions

Influenza Vaccines; Educational Status; Referral and Consultation

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Viral Vaccines; Vaccines; Biological Products; Complex Mixtures; Socioeconomic Factors; Population Characteristics; Professional Practice; Organization and Administration; Health Services Administration

Study Officials

• Katherine M Hiller, MD

  University of Arizona Department of Emergency Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: January 12, 2009
• First Posted: January 14, 2009
• Study Start: November 1, 2007
• Primary Completion: April 1, 2008
• Study Completion: April 1, 2008
• Last Updated: January 14, 2009

Record last verified: 2009-01

Locations

US (1)